对2.5%莫昔克丁/10%吡虫啉滴剂（Advocate®，Advantage® Multi）在实验感染血管圆线虫的犬只中的持续预防效果评估 - Suppr

Suppr

超能文献

Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.

作者信息

Böhm Claudia, Petry Gabriele, Schmidt Holger, Raue Katharina, Barthel Franziska, Schaper Roland

机构信息

Bayer Animal Health GmbH, 51368, Leverkusen, Germany.

BioMedVet Research GmbH, 29664, Walsrode, Germany.

出版信息

Parasitol Res. 2017 Aug;116(Suppl 1):1-10. doi: 10.1007/s00436-017-5487-x.

DOI:10.1007/s00436-017-5487-x

PMID:28717944

Abstract

摘要

相似文献

Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.

Parasitol Res. 2017 Aug;116(Suppl 1):1-10. doi: 10.1007/s00436-017-5487-x.

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate, Advantage Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs.

Parasitol Res. 2017 Aug;116(Suppl 1):65-74. doi: 10.1007/s00436-017-5492-0.

Evaluation of the Efficacy and Safety of an Imidacloprid 10 % / Moxidectin 1 % Spot-on Formulation (Advocate, Advantage Multi) in Cats Naturally Infected with Capillaria aerophila.

Parasitol Res. 2017 Aug;116(Suppl 1):55-64. doi: 10.1007/s00436-017-5491-1.

Efficacy and safety of imidacloprid/moxidectin spot-on solution and fenbendazole in the treatment of dogs naturally infected with Angiostrongylus vasorum (Baillet, 1866).

Vet Parasitol. 2007 Jul 20;147(3-4):258-64. doi: 10.1016/j.vetpar.2007.05.001. Epub 2007 Jun 4.

Efficacy of a single topical application of Advantage Multi (= Advocate) Topical Solution (10% imidocloprid + 2.5% moxidectin) in the treatment of dogs experimentally infected with Crenosoma vulpis.

Parasitol Res. 2009 Aug;105 Suppl 1:S49-54. doi: 10.1007/s00436-009-1495-9.

Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.

Parasitol Res. 2015 Aug;114 Suppl 1:S131-44. doi: 10.1007/s00436-015-4519-7.

Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio) for the prevention of angiostrongylosis in dogs presented as veterinary patients.

Parasit Vectors. 2020 Jul 29;13(1):385. doi: 10.1186/s13071-020-04262-4.

Efficacy of a moxidectin/imidacloprid spot-on formulation (Advocate) for the treatment of Troglostrongylus brevior in naturally infected cats in a field study in Greece.

Parasit Vectors. 2019 Nov 4;12(1):519. doi: 10.1186/s13071-019-3760-9.

Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study.

Parasitol Res. 2005 Oct;97 Suppl 1:S81-S88. doi: 10.1007/s00436-005-1449-9.

Efficacy of imidacloprid 10%/moxidectin 2.5% spot on (Advocate®, Advantage Multi®) and doxycycline for the treatment of natural Dirofilaria immitis infections in dogs.

Vet Parasitol. 2019 Sep;273:11-16. doi: 10.1016/j.vetpar.2019.07.011. Epub 2019 Jul 27.

引用本文的文献

Hemostatic Dysfunction in Dogs Naturally Infected with -A Narrative Review.

Pathogens. 2022 Feb 14;11(2):249. doi: 10.3390/pathogens11020249.

Simultaneous Exposure to and Vector-Borne Pathogens in Dogs from Italy.

Pathogens. 2021 Sep 15;10(9):1200. doi: 10.3390/pathogens10091200.

Spontaneous tricuspid valve chordal rupture in a dog with severe, irreversible pulmonary hypertension caused by Angiostrongylus vasorum infection.

BMC Vet Res. 2020 Aug 26;16(1):311. doi: 10.1186/s12917-020-02531-z.

Efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced infestations of five common tick species infesting dogs in the USA.

Parasit Vectors. 2020 Mar 1;13(1):77. doi: 10.1186/s13071-020-3945-2.

Feline Troglostrongylosis: Current Epizootiology, Clinical Features, and Therapeutic Options.

Front Vet Sci. 2018 Jun 20;5:126. doi: 10.3389/fvets.2018.00126. eCollection 2018.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验